At December’s American Society of Hematology (ASH) virtual meeting, data from the PHILEMON phase II trial were presented, which evaluated a regimen of ibrutinib, lenalidomide, and rituximab in patients with relapsed/refractory mantle cell lymphoma.
Following is a transcript of his remarks:
The MCL6 or PHILEMON trial is a similar type of trial [to the VALERIA study] actually, with a similar combination, but with ibrutinib instead of venetoclax. So this was the first study that studied this combination with R2 ibrutinib for relapsed refractory mantle cell lymphoma.
And there are 50 patients enrolled in this study, and at this year’s ASH, we presented a longer follow-up with the patients. And we see that we can establish a median progression-free survival which was 19 months.
So it’s quite comparable to ibrutinib alone. We could also see that patients with TP53 mutation and other high-risk features seem to have a similar outcome as patients without these characteristics.
So we still think that this may be a treatment option for high-risk mantle cell lymphoma at relapse. And we can also show that pre-treatment quality of life seem to be prognostic in this population. So patients with lower level of role functioning and emotional functioning had a worse prognosis. And also patients with more pain at baseline seemed to have worse prognosis.